



Duke at

*Virtual American Society
of Clinical Oncology 2020*

Beginning Friday, May 29 at 8:00 AM ET

- Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, will be available on demand.
- Registrants will have exclusive access to hundreds of video and slide presentations, as well as discussant commentary for 180 days.

Saturday, May 30

- **9:30 AM ET:** Opening Session with President's Address from Howard A. "Skip" Burris III, MD and Guest Speaker's Address by David Fajgenbaum, MD
- **10:30 AM ET:** Highlights Sessions: *Breast Cancer; Head and Neck Cancer*
- **11:00 AM ET:** Highlights Sessions: *Gastrointestinal Cancers; Central Nervous System Tumors*
- **11:30 AM ET:** Highlights Sessions: *Hematological Malignancies; Gynecological Cancers*
- **1:00 PM ET:** Special Clinical Science Symposium: *Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors*
- **2:30 PM ET:** Highlights Sessions: *Cancer Prevention, Risk Reduction, and Genetics; Symptoms and Survivorship*
- **3:30 PM ET:** Special Clinical Science Symposium: *Redefining Cancer of Unknown Primary: Is Genomics the Answer?*
- **4:30 PM ET:** Special Clinical Science Symposium: *Cancer Care in the time of COVID: Assessing Impact and Future Directions*

Sunday, May 31

- **9:30 AM ET:** Highlights Sessions: *Melanoma; Health Services Research and Quality Improvement*
- **10:00 AM ET:** Highlights Sessions: *Lung Cancer; Pediatric Oncology*
- **10:30 AM ET:** Special Clinical Science Symposium: *Drug Development for Rare Mutations: The Opportunity to Unite and Conquer*
- **1:00 PM ET:** Plenary Session
- **3:30 PM ET:** Highlights Sessions: *Genitourinary Cancers; Sarcoma*
- **4:00 PM ET:** Highlights Sessions: *Developmental Therapeutics; Care Delivery and Regulatory Policy*

ASCO Participation Provided by our Duke Colleagues:

Tian Zhang, MD

- A Featured Voice for #ASCO20 on Twitter
- Discussant for the Genitourinary Cancer—Kidney and Bladder poster discussion session; “Single agent targeted agents vs combinations with IO: what is the optimal future therapy in advanced urothelial cancer?”

Vishal Vashistha, MD

Abstract Title: Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.

Session Title: Care Delivery and Regulatory Policy

Session Type: Oral Abstract Session / Presenter

Date: Friday, May 29, 2020

Time: 8:00 AM - 11:00 AM

Abstract Discussant: Devika Govind Das, MBBS

Brent Hanks, MD, PhD

Discussant - Clinical Science Symposium

“Systems Biology Approaches to Immunotherapy Response and Toxicity”

Presentation entitled ‘Rise of the Machines: AI in Predicting Immunotherapy Outcomes’.

Landon Brown, MD

-Oral Presentation of abstract at ASCO 2020 under Dr. Andrew Armstrong’s mentorship; <https://meetinglibrary.asco.org/record/186713/abstract>

-Recipient - Conquer Cancer ASCO Merit Award for this abstract: “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types”; Abstract #: 3007

April Salama, MD

Poster Discussant for melanoma/skin cancers- “Characterizing Long Term Outcomes in Metastatic Melanoma in 2020”

Scientific Program Committee

Breast Cancer – Local/Regional/Adjuvant

Eun Sil (Shelby) Hwang, MD

Melanoma/Skin Cancers

April Salama, MD

E-Publications

Perceptions of process barriers to lung cancer screening at community oncology programs.

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Linda Sutton, Lisi Lotz, Eileen Horn V Horn, Trudy Pendergraft

ABSTRACT e19218

Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Syed Hussaini, Yi Ren, Meagan Lew, Lauren Bohannon, Jillian C Thompson, Yousuf Zafar, Anthony Derek Sung

ABSTRACT e19373

Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

SESSION

Publication Only: Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Benjamin Garnezy, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, Pavlos Msaouel, Amado J. Zurita, Paul Gettys Corn, Aradhana M. Venkatesan, Landon Carter Brown, Chester Kao, Emily Noelle Kinsey, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Matthew T Campbell

ABSTRACT e17090

Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

SESSION

Publication Only: Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Jeffrey Melson Clarke, Xiaofei F. Wang, Lin Gu, Marvaretta Miesha Stevenson, Tom Stinchcombe, Sundhar Ramalingam, Scott Joseph Antonia, Afreeen Shariff, Jennifer Garst, Jeffrey Crawford, Neal E. Ready

ABSTRACT e21683

A precision medicine drug discovery pipeline to identify dual CDK2/9 inhibition as a novel treatment for colorectal cancer.

SESSION

Publication Only: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Roham Salman Roghani, Ali Sanjari moghaddam, Gabrielle Rupprecht, Erdem Altunel, So Young Kim, Shannon McCall, Beatrice Thomas, Katie Ware, Jason Somarelli, David S. Hsu

ABSTRACT e16056

Missing data in breast cancer: Relationship with survival in national databases.

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Jennifer Kay Plichta, Christel N. Rushing, Holly C. Lewis, Dan G. Blazer, Terry Hyslop, Rachel Adams Greenup

ABSTRACT e19114

Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).

SESSION

Publication Only: Symptoms and Survivorship

AUTHOR(S)

Danielle M. Brander, Kevin C. Oeffinger, Melissa A. Greiner, Michaela Ann Dinan

ABSTRACT e24050

Fatigue trajectories in long-term non-Hodgkin lymphoma survivors.

SESSION

Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Matthew Roger LeBlanc, Sheryl Zimmerman, Mariam Kayle, Thomas William LeBlanc, Kathryn Elizabeth Hudson, Sophia Kostas Smith

ABSTRACT e20053

Patterns of inpatient palliative care consultation for patients with brain and spine metastases.

SESSION

Publication Only: Symptoms and Survivorship

AUTHOR(S)

Elizabeth Howell, Meghan Price, Tara Dalton, Theresa Williamson, Arif Kamal, Rory Goodwin

ABSTRACT e24117

Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).

SESSION

Publication Only: Breast Cancer—Metastatic

AUTHOR(S)

Elias Eteshola, Karenia Landa, Eun-Sil Shelley Hwang, Smita Nair, Bruce Sullenger
ABSTRACT e13096

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?

SESSION

Publication Only: Gynecologic Cancer

AUTHOR(S)

Haley Moss, Angeles Alvarez Secord, Jessica Perhanidis, Carol Hawkes

ABSTRACT e18042

An analysis of trends in prostate cancer treatment from a CMS database.

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Andre A. Konski, Elizabeth Lin Jewell, Laura J Havrilesky, Jason A. Efstathiou, Peter A. Johnstone

ABSTRACT e19288

A prospective cohort study of stability in preference for place of death among patients with stage IV cancer.

SESSION

Publication Only: Symptoms and Survivorship

AUTHOR(S)

Ling En Koh, Chetna Malhotra, Eric Finkelstein, COMPASS Study Group

ABSTRACT e24148

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

SESSION

Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Amy S. Ruppert, Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steve E. Coutre, Jennifer R. Brown, Sreenivasa R. Nattam, Richard A. Larson, Harry Paul Erba, Mark Robert Litzow, Carolyn Owen, Charles S. Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, John C. Byrd, Jennifer Ann Woyach

ABSTRACT e20004

Optimizing cancer care using digital technologies requires coordinated multi-stakeholder effort.

SESSION

Publication Only: Care Delivery and Regulatory Policy

AUTHOR(S)

Sendhilnathan Ramalingam, A Jay Holmgren, Jennifer Goldsack, Adam Conner-Simons, Edmondo Robinson

ABSTRACT e14108

Can a brief multimedia intervention facilitate breast cancer patients' communication about sexual health? Findings from a randomized controlled trial.

SESSION

Publication Only: Symptoms and Survivorship

AUTHOR(S)

Jennifer B. Reese, Mary Catherine Beach, Kristen A. Sorice, Whitney Pollard, Mary Beryl Daly, Elizabeth A. Handorf, Laura S Porter, James A. Tulsky, Stephen J Lepore

ABSTRACT e24179

An analysis of growth in the genetic counseling profession 2009 to 2019.

SESSION

Publication Only: Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)

Gillian Hooker, Dawn C. Allain, Adam H Buchanan, Melanie Care, Laura Conway, Alessandra Cumming, Shannan Dixon, Kristin Paulyson-Nuñez, Sara Riordan, Janet Williams

ABSTRACT e13526

Brain metastasis from esophageal squamous cell carcinoma: Clinical characteristics and prognosis.

SESSION

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S)

Linlin Xiao, Yvonne Marie Mowery, Jun Wang, Min Zhao, Shaowu Jing, Guangbin Gao

ABSTRACT e16525

Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey of patients with cancer.

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Robert S. Epstein, Matti S. Aapro, Upal K. Basu Roy, Tehseen Salimi, JoAnn Krenitsky, Megan L. Leone-Perkins, Jeffrey Crawford

ABSTRACT e19299

Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism.

SESSION

Publication Only: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S)

Jacob Kaufman; Duke University Medical Center, Durham, NC

ABSTRACT e21015

ASCO Virtual Scientific Program

Real-word incidence and management of durable complete response in de novo metastatic HER2-positive breast cancer.

SESSION

Publication Only: Breast Cancer—Metastatic

AUTHOR(S)

Claire Elizabeth Powers Smith, Paul Kelly Marcom, Zahi Ibrahim Mitri

ABSTRACT e13017

Long-term outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting.

SESSION

Publication Only: Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Stephen B. Williams, Lauren Howard, Meagan Foster, Zachary William Abraham Klaassen, Jan Sieluk, Haojie Li, Kentaro Imai, Eric Sbar, Amanda M. De Hoedt, Stephen J. Freedland

ABSTRACT e17031

Real-world examination of remission patterns in patients (pts) with acute myeloid leukemia (AML).

SESSION

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Ashley Tabah, David Huggar, Brenna L. Brady, Krutika Jariwala-Parikh, Ronda Copher, Thomas William LeBlanc

ABSTRACT e19336

Adult lymphoma-associated hemophagocytic lymphohistiocytosis: A clinical case series in a predominantly Hispanic cohort from the University of Miami/Jackson Memorial Hospital.

SESSION

Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Eduardo Edelman Saul, Amrita Desai, Jennifer Chapman, Lazaros J. Lekakis, Alexandra Stefanovic, Agustin Pimentel

ABSTRACT e20060

Multomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.

SESSION

Publication Only: Melanoma/Skin Cancers

AUTHOR(S)

Jinho Lee, Marilyne Labrie, Gen Yong, Todd Camp, Hongli Ma, Megan Grout, Wei Xu, **Georgia Beasley**, Lynn Mara Schuchter, Suzanne McGettigan, Donald M. O'Rourke, Meenhard Herlyn, Christopher L. Corless, Gordon B. Mills, Gao Zhang

ABSTRACT e22015

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

SESSION

Publication Only: Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Suresh S. Ramalingam, Tom Stinchcombe, Gregory James Gerstner, Missak Haigentz, Surya Vangala, Megan Parsi, John W. Heyburn, Victor Kabala, Tuhina Prasad, Andres A. Gutierrez, Jonathan Wade Goldman, ADXS-503 Author's Group

ABSTRACT e21682

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).

SESSION

Publication Only: Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)

Daniel Louis Hertz, Nicholas Bradley Larson, Timothy Pierpont, Nancy L. Bartlett, Andrew David Zelenetz, Wyndham Hopkins Wilson, John Paul Leonard, Sin-Ho Jung, Shaun M. Riska, Kristy L. Richards

ABSTRACT e13535

Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.

SESSION

Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Jasmine Jiemei Wang, Pai-Chi Teng, Yu Jen Jan, Jie-Fu Chen, Galen Cook-Wiens, Nu Yao, Gina Chia-Yi Chu, Pin-Jung Chen, Hao Ho, Yi-Te Lee, Jiaoti Huang, Ker-Chau Li, Leland WK Chung, Yazhen Zhu, Michael Freeman, Andre Rogatko, Ju Dong Yang, Hsian-Rong Tseng, Edwin Melencio Posadas

ABSTRACT e17512

Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.

SESSION

Publication Only: Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Meaghan Dendy Case, Anish Ghodadra, Paula M. Novelli, Vincent Wu, Suvranu Ganguli, Moritz Wildgruber, Michael Kohler, Charles Robinson, Charles Kim, David S. Wang, Daniel Y. Sze, Kenneth Kolbeck, Lori Russell, Johannes M. Ludwig, Johannes Uhlig, Kevin Kim

ABSTRACT e16119

Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321.**SESSION**

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Lisa M. Kopp, Damon R. Reed, Safia K. Ahmed, Wendy Allen-Rhoades, Viswatej Avutu, Yen-Lin Chen, Lara E. Davis, Bree Ruppert Eaton, Douglas S. Hawkins, Daniel J. Indelicato, Shreyaskumar Patel, R. Lor Randall, Denise K. Reinke, Richard F. Riedel, Thomas Scharschmidt, Katherine Anne Thomson, Dian Wang, Katherine A. Janeway, Aaron R. Weiss

ABSTRACT e19214

Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.**SESSION**

Publication Only: Health Services Research and Quality Improvement

AUTHOR(S)

Christina D Williams, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael J. Kelley

ABSTRACT e19295

Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.**SESSION**

Publication Only: Symptoms and Survivorship

AUTHOR(S)

Lee S. Schwartzberg, Rudolph M. Navari, Kathryn Jean Ruddy, Thomas William LeBlanc, Rebecca Anne Clark-Snow, Rita S. Wickham, Gary Binder, William Bailey, Marco Turini, Ravi C. Potluri, Luke M. Schmerold, Eric Roeland,

ABSTRACT e24133

The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).**SESSION**

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S)

Lipika Goyal, Angela Lamarca, John H. Strickler, Michael Cecchini, Daniel H. Ahn, Islam Baiev, Alice Boileve, Melodie Tazdait, Lindsay Marie Hannan, Jingquan Jia, Hetal Desai Marble, Afsaneh Barzi, Vaibhav Sahai, Jochen K Lennerz, Robin Kate Kelley, Tanios S. Bekaii-Saab, Milind M. Javle, Nataliya Volodymyrivna Uboha, William P. Harris, Antoine Hollebecque

ABSTRACT e16686

GI

Predictive and prognostic value of *HER2* gene expression and *HER2* amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).

SESSION

Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Francesca Battaglin, Fang-Shu Ou, Xueping Qu, Monica M. Bertagnolli, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Tyler J. Zemla, Charles David Blanke, Alan P. Venook, Omar Kabbarah, Heinz-Josef Lenz, Federico Innocenti

ABSTRACT / POSTER 4086 • 78

Characterization of sociodemographic and clinicopathological features and associated outcomes of patients (Pts) with anal squamous cell cancer (ASCC): Analysis of 44,084 pts in the National Cancer Database (NCDB).

SESSION

Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Joanna Alyse Young, Sally Jeanne Trufan, William Mills Worriow, Laura W. Musselwhite, Reza Nazemzadeh, Kunal C. Kadakia, Seungjean Chai, John Stuart Salmon, Jimmy J. Hwang, Edward S. Kim, Derek Raghavan, Mohamed E. Salem

ABSTRACT / POSTER 4052 • 44

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.

SESSION

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S)

Ulrich Ronellenfitsch, Katrin Jensen, Svenja Seide, Meinhard Kieser, Matthias Schwarzbach, Tracy E Slanger, Bryan Burmeister, David Paul Kelsen, Donna Niedzwiecki, Guillaume Piessen, Christoph Schumacher, Susan Urba, Cornelis J. H. Van De Velde, Marc Ychou, Ralf Dieter Hofheinz, Sylvie Lorenzen

ABSTRACT / POSTER 4533 • 141

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

SESSION

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S)

Jennifer Rachel Eads, Michelle Weitz, Michael K. Gibson, Lakshmi Rajdev, Onkar V Khullar, Steven H. Lin, Constantine Gatsonis, Ignacio Ivan Wistuba, Aravind Sanjeevaiah, Al Bowen Benson, Nathan Bahary, Kristen Renee Spencer, Nabil F. Saba, Stanley R. Hamilton, Charles A. Staley, Anuradha Bapsi Chakravarthy, Terence Z. Wong, Peter J. O'Dwyer

ABSTRACT / POSTER TPS4651 • 259

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

SESSION

Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler J. Zemla, Priya Kumthekar, Katherine A Guthrie, Felix Couture, J. Phillip Kuebler, Johanna C. Bendell, Pankaj Kumar, DeQuincy Andrew Lewis, Benjamin R. Tan, Monica M. Bertagnolli, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Alan P. Venook, Charles David Blanke, Anthony Frank Shields

ABSTRACT 4003

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS^{G12C}, in patients with advanced colorectal cancer.

SESSION

Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Marwan Fakih, Jayesh Desai, Yasutoshi Kuboki, John H. Strickler, Timothy Jay Price, Greg Andrew Dum, Gerald Steven Falchook, Crystal S. Denlinger, John C. Krauss, Geoffrey Shapiro, Tae Won Kim, Keunchil Park, Andrew L. Coveler, Pamela N. Munster, Bob T. Li, June Kim, Haby Adel Henary, Gatarae Ngamchamnanrith, David S. Hong

ABSTRACT / POSTER 4018 • 10

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

SESSION

Gastrointestinal Cancer—Colorectal and Anal

AUTHOR(S)

Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, Johanna C. Bendell, Thomas Gruenberger, Gianluca Masi, Elena Ongaro, Herbert Hurwitz, Alfredo Falcone, Hans-Joachim Schmoll, Massimo Di Maio

ABSTRACT / POSTER 4015 • 7

Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

SESSION

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

AUTHOR(S)

Eugene R Ahn, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Carmen Julia Calfa, Ajjai Shivaram Alva, Vijay S. Suhag, Omid Hamid, Efrat Dotan, Eddy Shih-Hsin Yang, Olatunji B. Alese, Kathleen J Yost, Alissa S. Marr, Martin Clive Palmer, Forrest L. Thompson, Andrew Lawrence Rygiel, Sarah T. Anderson, Samiha Islam, Richard L. Schilsky
ABSTRACT / POSTER 4637 • 245

Sarcoma

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).

SESSION

Sarcoma

AUTHOR(S)

Matthew Ingham, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, Anthony D. Elias, David A. Liebner, Mark Agulnik, Katherine Anne Thomson, Varun Monga, Brian Andrew Van Tine, Gary K. Schwartz, William D. Tap

ABSTRACT / POSTER 11562 • 450

Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.

SESSION

Sarcoma

AUTHOR(S)

Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, Erlinda Maria Gordon, Jason L. Hornick, David J. Kwiatkowski, Heng Du, Berta Grigorian, Anita N. Schmid, Shihe Hou, Katherine Harris, Neil Desai, Mark Andrew Dickson

ABSTRACT / POSTER 11516 • 404

GU

Patient preferences and expectations of systemic therapy in renal cell carcinoma.

SESSION

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Dena Battle, Cristiane Decat Bergerot, Pavlos Msaouel, Eric Jonasch, Tian Zhang, Daniel J. George, Michael D. Staehler

ABSTRACT / POSTER 5083 • 152

Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.

SESSION

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Dena Battle, Cristiane Decat Bergerot, Pavlos Msaouel, Tian Zhang, Daniel J. George, Michael D. Staehler

ABSTRACT / POSTER 5084 • 153

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

SESSION

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Tian Zhang, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, Tyler J. Zemla, Hamid Emamekhoo, Ulka N. Vaishampayan, Michael J. Morris, Daniel J. George, Toni K. Choueiri

ABSTRACT / POSTER TPS5100 • 169

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Emerson A. Lim, Todd Michael Bauer, Manish R. Patel, Gerald Steven Falchook, Janet L. Karlix, Jennifer Hsing Choe, Daniel J. George, Ganesh M. Mugundu, Elizabeth Pilling, Huifang Chen, Bolan Linghu, Lara McGrath, Wenlin Shao, Melinda S. Merchant, Ben Sidders, Kris F. Sachsenmeier, Gayle Pageau Pouliot, Charles G. Drake, Johanna C. Bendell

ABSTRACT / POSTER 5518 • 99

Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Catherine Handy Marshall, Jong Chul Park, Wei Fu, Hao Wang, Theodore L. DeWeese, Serina King, Michaela Afful, Julia Hurrelbrink, Charlotte Manogue, Patrick Cotogno, Nancy P. Moldawer, Pedro C. Barata, Charles G. Drake, Edwin Melencio Posadas, Andrew J. Armstrong, A. Oliver Sartor, Emmanuel S. Antonarakis

ABSTRACT / POSTER 5563 • 144

Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Lin Wang, Channing Judith Paller, Hwanhee Hong, Anthony De Felice, Caleb Alexander, Otis W. Brawley

ABSTRACT / POSTER 5532 • 113

DAROL: DARolutamide Observational study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Evan Y. Yu, Christopher Michael Pieczonka, Alberto Briganti, Declan G. Murphy, Thierry Lebret, Murilo Luz, Hiroyoshi Suzuki, Antoine Thierry-Vuillemin, Jorge A. Ortiz, Rongjin Guan, Andrew J. Armstrong

ABSTRACT / POSTER TPS5593 • 174

DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Tomasz M. Beer, Neal D. Shore, Alicia K. Morgans, Kerri M. Winters-Stone, Jeffrey Scott Wefel, Jorge A. Ortiz, John A. Reeves, Daniel J. George

ABSTRACT / POSTER TPS5587 • 168

Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Shan Jiang, Emi Terasawa, Viviana Garcia Horton, Rajeev Ayyagari, A. Reginald Waldeck, Susan Halabi, Neal D. Shore
ABSTRACT / POSTER 5561 • 142

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.**SESSION**

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Jonathan E. Rosenberg, Thomas W. Flaig, Terence W. Friedlander, Matthew I. Milowsky, Sandy Srinivas, Daniel Peter Petrylak, Jaime R. Merchan, Mehmet Asim Bilen, Anne-Sophie Carret, Nancy Yuan, Carolyn Sasse, Christopher J. Hoimes
ABSTRACT / POSTER 5044 • 113

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.**SESSION**

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Hristos Z. Kaimakiotis, Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L Smith, Radhika Walling, Timothy A. Masterson, Adam C Calaway, Michael O. Koch, Elizabeth Sondeman, Pingfu Fu, Gordon Goolamier, Cheryl Eitman, Lee Evan Ponsky, Christopher J. Hoimes
ABSTRACT / POSTER 5019 • 88

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).**SESSION**

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Naomi B. Haas, Maneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti, David Cella, Rajan T. Gupta, Brian M. Shuch, Primo Lara, Anil Kapoor, Daniel Yick Chin Heng, Bradley C. Leibovich, M Dror Michaelson, Toni K. Choueiri, Michael A.S. Jewett, Deb Maskens, Lauren C Harshman, Viraj A. Master, Michael Anthony Carducci
ABSTRACT / POSTER TPS5101 • 170

HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.**SESSION**

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Neal D. Shore, Daniel J. George, Fred Saad, Michael Cookson, Daniel R. Saltzstein, Ronald F. Tutrone, Hideyuki Akaza, Alberto Bossi, David van Veenhuizen, Bryan Selby, Xiaolin Fan, Vicky Kang, Jacqueline M. Walling, Bertrand F. Tombal
ABSTRACT 5602

Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES *post hoc* analyses.**SESSION**

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Neal D. Shore, Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak, Jeffrey Holzbeierlein, Amauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Amulf Stenzl
ABSTRACT / POSTER 5547 • 128

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.**SESSION**

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Evan P. Pisick, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Eddy Shih-Hsin Yang, Elie G. Dib, Earle Frederick Burgess, Michael Howard Zakem, Nitin Rohatgi, Mehmet Asim Bilen, Sasha L. Warren, Sarah T. Anderson, Andrew Lawrence Rygiel, Richard L. Schilsky
ABSTRACT / POSTER 5567 • 148

Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).**SESSION**

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

W. Kevin Kelly, Daniel Costin Danila, William Jeffery Edenfield, Rahul Raj Aggarwal, Daniel Peter Petrylak, A. Oliver Sartor, Christopher Joseph Sumey, Tanya B. Dorff, Evan Y. Yu, Nabil Adra, David Michael Waterhouse, Andrew J. Armstrong, Lisa Horvath, David William Pook, Leonard Joseph Appleman, Aubrey Lau, Mark Salvati, Hosein Kouros-Mehr
ABSTRACT / POSTER TPS5589 • 170

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)-eligible cohort of HCRN GU14-188.**SESSION**

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Christopher J. Hoimes, Nabil Adra, Mark T. Fleming, Hristos Z. Kaimakiotis, Joel Picus, Zachary L Smith, Radhika Walling, Edouard John Trabulsi, Jean H. Hoffman-Censits, Michael O. Koch, Clint Cary, Robert Abouassaly, Cheryl Eitman, Pingfu Fu, Gordon Goolamier, Adam C Calaway, Lee Evan Ponsky, William Kevin Kelly
ABSTRACT / POSTER 5047 • 116

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.

SESSION

Genitourinary Cancer—Kidney and Bladder

AUTHOR(S)

Nataliya Mar, Terence W. Friedlander, Christopher J. Hoimes, Thomas W. Flaig, Mehmet Asim Bilen, Arjun Vasant Balar, Elizabeth Henry, Sandy Srinivas, Jonathan E. Rosenberg, Daniel Peter Petrylak, Earle Frederick Burgess, Jaime R. Merchan, Scott T. Tagawa, Anne-Sophie Carret, Joyce Leta Steinberg, Marya F. Chaney, Matthew I. Milowsky

ABSTRACT / POSTER TPS5092 • 161

Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Michael J. Morris, Lawrence Fong, Daniel Peter Petrylak, A. Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Shivaram Alva, Leonard Joseph Appleman, Winston Tan, Ulka N. Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward Ernest Kadel, Kobe Chi Yung Yuen, Asim Datye, Andrew J. Armstrong

ABSTRACT / POSTER 5565 • 146

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Elisa Marie Ledet, Ellen Jaeger, Whitley Hatton, Marcus W. Moses, Alexandra Sokolova, Mari Nakazawa, Jason Zhu, Beth Dellinger, Sara Elrefai, Rana R. McKay, Heather H. Cheng, Earle Frederick Burgess, Emmanuel S. Antonarakis, A. Oliver Sartor

ABSTRACT / POSTER 5568 • 149

KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Christopher J. Hoimes, Julie N Graff, Scott T. Tagawa, Clara Hwang, Deepak Kilari, A. J. Ten Tije, Aurelius Omlin, Raymond S. McDermott, Ulka N. Vaishampayan, Tony Elliott, Winald R. Gerritsen, Haiyan Wu, Jeri Kim, Charles Schloss, Johann S. De Bono, Emmanuel S. Antonarakis

ABSTRACT / POSTER 5543 • 124

Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Daniel Eidelberg Spratt, Shawn Malone, Soumyajit Roy, Scott Grimes, Libni Eapen, Scott Carlyle Morgan, Julia Malone, Julia Craig, Robert Timothy Dess, William Jackson, Matthew J Schipper, Jeff M. Michalski, W. Robert Lee, Thomas Michael Pisansky, Felix Y Feng, William U. Shipley, Howard M. Sandler, Mack Roach, Yilun Sun, Colleen Anne Lawton

ABSTRACT / POSTER 5584 • 165

Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Evan Y. Yu, Jose Maria M. Piulats Rodriguez, Gwenaelle Gravis, Brigitte Laguerre, Jose Angel Arranz Arija, Stephane Oudard, Peter C.C. Fong, Michael Paul Kolinsky, Marinela Augustin, Tilman Todenhofer, Audrey E. Kam, Howard Gurney, Ali Tafreshi, Margitta Retz, William R. Berry, Nataliya Mar, Haiyan Wu, Ping Qiu, Charles Schloss, Johann S. De Bono

ABSTRACT / POSTER 5544 • 125

Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Srikala S. Sridhar, Michael Paul Kolinsky, Gwenaelle Gravis, Loic Mourey, Jose Maria M. Piulats Rodriguez, Emanuela Romano, William R. Berry, Howard Gurney, Margitta Retz, Leonard Joseph Appleman, Martin Boegemann, Johann S. De Bono, Anthony M. Joshua, Urban Emmenegger, Henry Jacob Conter, Brigitte Laguerre, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu

ABSTRACT / POSTER 5550 • 131

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

SESSION

Genitourinary Cancer—Prostate, Testicular, and Penile

AUTHOR(S)

Henry Jacob Conter, Neal D. Shore, William R. Berry, Peter C.C. Fong, Jose Maria M. Piulats Rodriguez, Leonard Joseph Appleman, Tilman Todenhöfer, Gwenaelle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Loic Mourey, Johann S. De Bono, Audrey E. Kam, Urban Emmenegger, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu

ABSTRACT / POSTER 5545 • 126

Lung

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

SESSION

Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Natasha B. Leighl, Mary Weber Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, James Lloyd Wade, William Johnson Irvin, Sreekanth Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Tom Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Vassiliki Papadimitrakopoulou, Karen Kelly

ABSTRACT / POSTER 9623 • 389

AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).

SESSION

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S)

Helen J. Ross, David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrene, Ilze Bara, Mayank Gandhi, Katja Schulze, JaneMichelle Michelle Brockman, Xiaofei F. Wang, Junheng Gao, Everett E. Vokes, Tom Stinchcombe

ABSTRACT / POSTER 9045 • 238

Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).

SESSION

Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Joao Victor Machado Alessi, Carolyn Glass, Biagio Ricciuti, Liam F. Spurr, Lynette M. Sholl, Mark M. Awad

ABSTRACT / POSTER 9577 • 343

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.

SESSION

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S)

Helen J. Ross, Chen Hu, Kristin Ann Higgins, Salma K. Jabbour, David E. Kozono, Taofeek Kunle Owonikoko, Benjamin Movsas, Timothy Solberg, Canhua Xiao, Terence Marques Williams, James William Welsh, Jeffrey Simko, Xiaofei F. Wang, Nisha Anjali Mohindra, Charles Hsu, Tom Stinchcombe, Jeffrey Bradley

ABSTRACT / POSTER TPS9082 • 275

Pozitotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

SESSION

Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Xiuning Le, Jonathan Wade Goldman, Jeffrey Melson Clarke, Nishan Tchekmedyian, Zofia Piotrowska, David Chu, Gajanan Bhat, Francois M. Lebel, Mark A. Socinski

ABSTRACT / POSTER 9514 • 280

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).

SESSION

Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Andreas Nicholas Saltos, Tawee Tanvetyanon, Ben C. Creelan, Michael Rahman Shafique, Scott Joseph Antonia, Eric B. Haura, Hong Zheng, Margaret Barlow, James Saller, Anna Castellano-Fornelli, Antoine Richards, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A Beg, Jhanelle Elaine Gray

ABSTRACT / POSTER 9567 • 333

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

SESSION

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S)

Joseph W. Kim, Navid Hafez, Hatem Hussein Soliman, Siqing Fu, Shumei Kato, Primo Lara, Ulka N. Vaishampayan, Albiruni Ryan Abdul Razak, Dana Backlund Cardin, Pamela N. Munster, Joseph Paul Eder, Elizabeth M. Swisher, Andrew B. Nixon, Abhijit Patel, Yu Shyr, S. Percy Ivy, Patricia LoRusso

ABSTRACT / POSTER 9065 • 258

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

SESSION

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

AUTHOR(S)

Jacob Sands, Sumithra J. Mandrekar, Geoffrey R. Oxnard, David E. Kozono, Shauna L Hillman, Suzanne Eleanor Dahlberg, Zhuoxin Sun, Jamie E. Chaff, Ramaswamy Govindan, David E. Gerber, Jhanelle Elaine Gray, Shakun M. Malik, Margaret M. Mooney, Pasi A. Janne, Everett E. Vokes, Karen Kelly, Suresh S. Ramalingam, Tom Stinchcombe

ABSTRACT / POSTER TPS9077 • 270

Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

SESSION

Lung Cancer—Non-Small Cell Metastatic

AUTHOR(S)

Justin F. Gainor, Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Rybkin, Pavan S. Reddy, Leora Horn, Julie R. Brahmer, Bruno R. Bastos, Mark M. Awad, Matthew David Hellmann, Suresh S. Ramalingam, **Neal E. Ready**, David R. Spigel, Ravi S. Kasinathan, Cécile Dorange, Hossein Borghaei

ABSTRACT / POSTER 9560 • 326

Breast

Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery.

SESSION

Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)

Marc D Ryser, Laura Hendrix, Samantha M. Thomas, Thomas Lynch, Anne McCarthy, Zahed Mohammed, Amanda B. Francescatti, Elizabeth S. Frank, Ann H. Partridge, Alastair Mark Thompson, Terry Hyslop, Eun-Sil Shelley Hwang

ABSTRACT / POSTER 519 • 11

Identification of pathogenic *ROS1* alterations in cell-free DNA (cfDNA) from patients with breast cancer.

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Jeremy Meyer Force, Mary Love Taylor, Leylah Drusbosky, Jennifer Yen, Paul Kelly Marcom, Carey K. Anders, Jeffrey R Marks

ABSTRACT / POSTER 1031 • 116

Disparities in receipt of and time to adjuvant therapy after lumpectomy.

SESSION

Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)

Irene Dankwa-Mullan, M. Christopher Roebuck, Joseph Tkacz, Oluwadamilola Motunrayo Fayanju, Yi Ren, Gretchen Purcell Jackson, Yull Edwin Ariaga

ABSTRACT / POSTER 534 • 26

Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center wake forest NCORP research-base study.

SESSION

Breast Cancer—Local/Regional/Adjuvant

AUTHOR(S)

Susan Faye Dent, Kerryn Reding, Glenn Jay Lesser, Heidi D. Klepin, Lynne I. Wagner, Dalane Kitzman, Peter H. Brubaker, Shannon Mihalko, Nancy E. Avis, Karen Marie Winkfield, Bonnie Ky, Teresa Crofts, Robin Kikuchi, Tonya Calhoun, W. Gregory Hundley

ABSTRACT / POSTER TPS602 • 94

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Faye Dent, Miguel Martin, Alistair E. Ring, Paul H. Cottu, Janice M. Lu, Eva Ciruelos, Hamdy A. Azim, Sanjoy Chatterjee, Katie Zhou, Jiwen Wu, Nii Ankrh, Claudio Zamagni

ABSTRACT / POSTER 1055 • 140

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Navid Hafez, Hatem Hussein Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Munster, Ulka N. Vaishampayan, Shumei Kato, Primo Lara, Elizabeth M. Swisher, Andrew B. Nixon, Abhijit Patel, Yu Shyr, S. Percy Ivy, Patricia LoRusso, Joseph W. Kim

ABSTRACT / POSTER 1077 • 162

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Patricia LoRusso, Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisin M. Connolly, Erin Elizabeth Roesch, Anosheh Afghahi, Hyo S. Han, Rita Nanda, Gerburg M. Wulf, Hadeel Assad, Haeseong Park, Elizabeth Claire Dees, Jeremy Meyer Force, Anne M. Noonan, Adam Brufsky, Vandana G Abramson, Barbara B. Haley, Sandra S. Buys, Elad Sharon, Kurt A. Schalper

ABSTRACT / POSTER TPS1102 • 187

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Nancy U. Lin, Rashmi Krishna Murthy, Carey K. Anders, Virginia F. Borges, Sara A. Hurvitz, Sherene Loi, Vandana G Abramson, Philippe L. Bedard, Mafalda Oliveira, Amelia Bruce Zelnak, Michael DiGiovanna, Thomas Bachelot, Amy Jo Chien, Ruth O'Regan, Andrew M. Wardley, Volkmar Müller, Lisa A. Carey, Suzanne M. McGoldrick, Grace An, Eric P. Winer

ABSTRACT 1005

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline *BRCA*-associated breast cancer (SWOG S1416).

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Priyanka Sharma, Eve Rodler, William E. Barlow, Julie Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders, Lori J. Goldstein, Ursa Abigail Brown-Glaberman, Thu-Tam Huynh, Christopher Scott Szyarto, Andrew K. Godwin, Harsh B Pathak, Elizabeth M. Swisher, Marc R Radke, Kirsten M Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi

ABSTRACT 1001

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

SESSION

Breast Cancer—Metastatic

AUTHOR(S)

Nadine M. Tung, Mark E. Robson, Steffen Ventz, Cesar Augusto Santa-Maria, Paul Kelly Marcom, Rita Nanda, Payal D Shah, Tarah Jean Ballinger, Eddy Shih-Hsin Yang, Michelle E. Melisko, Adam Brufsky, Shaveta Vinayak, Michelle Demeo, Colby Jenkins, Susan M. Domchek, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy Ellen Garber

ABSTRACT 1002

Central Nervous System

BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.

SESSION

Central Nervous System Tumors

AUTHOR(S)

Katherine B. Peters, Adam Louis Cohen, Nicholas A. Butowski, John L. Villano, Pierre Giglio, Tresa McGranahan, Chi Zhang, Timothy Francis Cloughesy, James Emmett Herndon, Patrick Healy, David MacLeod, Sara Penchev, David Silberstein, Ines Batinic-Haberle, Ivan Spasojevic, Shayne Gad, David Radoff, Daniel Barboriak, James Crapo

ABSTRACT / POSTER TPS2577 • 68

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

SESSION

Central Nervous System Tumors

AUTHOR(S)

Annick Desjardins, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O Johnson, Stevie Threatt, Chevelle A Bullock, James Emmett Herndon, Patrick Healy, Eric S Lipp, John H. Sampson, Allan H. Friedman, Henry S. Friedman, David M. Ashley, Darell D. Bigner

ABSTRACT / POSTER 2566 • 57

Alliance A071701: Genomically guided treatment trial in brain metastases.

SESSION

Central Nervous System Tumors

AUTHOR(S)

Priscilla Kaliopi Brastianos, Erin Twohy, Carey K. Anders, A. John Iafrate, Peter A. Kaufman, Justine Vanessa Cohen, Rebecca Suk Heist, Elizabeth Robins Gerstner, Timothy J. Kaufmann, Susan Geyer, Laura Hoffman, Priya Kumthekar, Frederick G. Barker, Scott L. Carter, Paul D. Brown, Evanthia Galanis

ABSTRACT / POSTER TPS2573 • 64

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.

SESSION

Central Nervous System Tumors

AUTHOR(S)

Ingo K. Mellingerhoff, Katherine B. Peters, Timothy Francis Cloughesy, Howard A. Burris III, Elizabeth Anne Maher, Filip Janku, Gregory Michael Cote, Macarena Ines De La Fuente, Jennifer Leigh Clarke, Kha Le, Li Liu, Man Yuen, Marissa Arnofsky, Islam Hassan, Lori Steelman, Shuchi Sumant Pandya, Patrick Y. Wen

ABSTRACT 2504

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

SESSION

Central Nervous System Tumors

AUTHOR(S)

Ingo K. Mellingerhoff, Martin J. Van Den Bent, Jennifer Leigh Clarke, Elizabeth Anne Maher, Katherine B. Peters, Mehdi Touat, John Frederick De Groot, Macarena Ines De La Fuente, Isabel Arillaga-Romany, Wolfgang Wick, Benjamin M. Ellingson, Steven Schoenfeld, Feng Tai, Kha Le, Min Lu, Lori Steelman, Islam Hassan, Shuchi Sumant Pandya, Patrick Y. Wen, Timothy Francis Cloughesy

ABSTRACT / POSTER TPS2574 • 65

Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

SESSION

Central Nervous System Tumors

AUTHOR(S)

Antonio Marcilio Padula Omuro, Lisa Marie DeAngelis, Theodore Karrison, Joe A Bovi, Marc Rosenblum, Benjamin W. Com, Denise Correa, Jeffrey Scott Wefel, Sanjay Aneja, Christian Grommes, Lauren Schaff, Steven E. Waggoner, Enrico C. Lallana, Maria Wemer-Wasik, Fabio Iwamoto, Timothy J. Robinson, Eric Donnelly, Timothy Struve, Minhee Won, Minesh P. Mehta

ABSTRACT 2501

MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.

SESSION

Central Nervous System Tumors

AUTHOR(S)

John H. Sampson, Achal Achrol, Manish K. Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Jacob Brenner, Chandtip Chandhasin, Sajeel A. Chowdhary, Melissa Coello, Sunit Das, Seunggu Jude Han, Santosh Kesari, Fahar Merchant, Nina Merchant, Dina Randazzo, Michael A. Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas A. Butowski

ABSTRACT / POSTER 2513 • 4

Molecular features of gliomas with high tumor mutational burden.

SESSION

Central Nervous System Tumors

AUTHOR(S)

Joanne Xiu, Kyle M Walsh, Manjari Pandey, Emil Lou, Ekokobe Fonkem, Herbert B. Newton, Erin M. Dunbar, Macarena Ines De La Fuente, Michael J. Glantz, Sandeep Mittal, David M. Ashley, Wolfgang Michael Kom, Ashley Love Sumrall

ABSTRACT / POSTER 2549 • 40

Hem Malignancies

A phase I/II study of IMG632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

SESSION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHOR(S)

Naval Guastad Daver, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Elisabetta Todisco, Corrado Tarella, Giovanni Martinelli, Harry Paul Erba, Eric Deconinck, Kendra L. Sweet, Roland B. Walter, Moshe Yair Levy, Naveen Pemmaraju, Andrew A. Lane, David Rizzieri, Marina Konopleva, Callum Mortimer Sloss, Jiuzhou Wang, Kara E. Malcolm, Patrick A. Zweidler-McKay

ABSTRACT / POSTER TPS7563 • 336

A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMG632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.

SESSION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHOR(S)

Naval Guastad Daver, Eunice S. Wang, Kendra L. Sweet, Pau Montesinos, Harry Paul Erba, Daniel J. DeAngelo, Callum Mortimer Sloss, Jiuzhou Wang, Kara E. Malcolm, Patrick A. Zweidler-McKay

ABSTRACT / POSTER TPS7564 • 337

A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.

SESSION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHOR(S)

Thomas William LeBlanc, Roland B. Walter, Lioriana Hernandez, Lucy Morgan, Timothy Bell, Charlotte Panter, Francois Peloquin, Jasmine Healy, Adam Gater, Verna Welch, Karim Amer, Louise O'Hara, Ryan Hohman, Andrew Brown, Nigel Russell, Diana M. Merino, Neil Horikoshi, Dawn Maze

ABSTRACT / POSTER 7520 • 293

Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.

SESSION

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Kai Fu, Guohua Yu, Chengfeng Bi, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad, Brian K. Link, Craig R. Nichols, Paul M. Barr, Brad S. Kahl, Douglas Stewart, Stefan K. Barta, Anne Beaven, Ranjana H. Advani, Peter Martin, Timothy Greiner, Dennis Weisenburger, James O. Armitage, Julie Vose

ABSTRACT / POSTER 8035 • 368

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

SESSION

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Sarah C. Rutherford, Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li, Michael Leo LeBlanc, Kristie A. Blum, Travis Dockter, Peter Martin, Sin-Ho Jung, Barbara W. Grant, Cara Ann Rosenbaum, Chaitra Shankar Ujjani, Paul M. Barr, Joseph M. Unger, Bruce D. Cheson, Nancy L. Bartlett, Jonathan W. Friedberg, John Paul Leonard

ABSTRACT / POSTER 8038 • 371

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

SESSION

Hematologic Malignancies—Plasma Cell Dyscrasia

AUTHOR(S)

Shaji Kumar, Simon J. Harrison, Michele Cavo, Javier de La Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Francesca Gay, Gabor Mikala, Elizabeth Punnoose, Wan-Jen Hong, Anjia Sood, Muhammad Jalaluddin, Jeremy A. Ross, James M. Pauff, Paulo Cesar Maciag, Philippe Moreau

ABSTRACT / POSTER 8509 • 409

Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.

SESSION

Hematologic Malignancies—Plasma Cell Dyscrasia

AUTHOR(S)

Sikander Ailawadhi, Hans Chulhee Lee, Jim Omel, Kathleen Toomey, James W. Hardin, Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. Durie, Mohit Narang, Howard R. Terebello, Lynne I. Wagner, Mazaher Dhalla, Mia He, Shankar Srinivasan, Prashant Ramesh Joshi, Suzanne Robinson, Rafat Abonour

ABSTRACT / POSTER 8518 • 418

Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.

SESSION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHOR(S)

Tracy George, Jay L. Patel, Mehrdad Abedi, Christopher R. Cogle, Harry Paul Erba, Guillermo Garcia-Manero, David L. Grinblatt, Pavel Kiselev, Rami S. Komrokji, Chrystal Ursula Louis, Jaroslaw P. Maciejewski, Melissa Nifenecker, Daniel Aaron Pollyea, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, David P. Steensma, Michael A. Thompson, Kathryn Foucar

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

SESSION

Hematologic Malignancies—Plasma Cell Dyscrasia

AUTHOR(S)

Cristina Gasparetto, Suzanne Lentzsch, Gary J. Schiller, Natalie Scott Callander, Sascha Tuchman, Nizar J. Bahlis, Darrell White, Christine Chen, Muhamed Baljevic, Heather J Sutherland, Rami Kotb, Michael Sebag, Richard LeBlanc, Christopher P Venner, William Bensinger, Adriana C. Rossi, Heidi Sheehan, Melina Arazy, Kazuharu Kai, Brea Lipe

ABSTRACT / POSTER 8510 • 410

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

SESSION

Hematologic Malignancies—Plasma Cell Dyscrasia

AUTHOR(S)

Cristina Gasparetto, Brea Lipe, Sascha Tuchman, Natalie Scott Callander, Suzanne Lentzsch, Muhamed Baljevic, Adriana C. Rossi, Nizar J. Bahlis, Darell White, Christine Chen, Heather J Sutherland, Rami Kotb, Richard LeBlanc, Michael Sebag, Christopher P Venner, William Bensinger, Heidi Sheehan, Yawen Ju, Kazuharu Kai, Gary J. Schiller

ABSTRACT / POSTER 8530 • 430

Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.

SESSION

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHOR(S)

Jorge E. Cortes, Elza Lomaia, Anna Turkina, Beatriz Moiraghi, Maria Undurruga Sutton, Carolina Pavlovsky, Christine Rojas, Charles Chuah, Christopher Kevin Arthur, Jane Apperley, Dong-Wook Kim, Andreas Hochhaus, Philippe H. Rousselot, Gianantonio Rosti, Michael J. Mauro, Jeffrey Howard Lipton, Daniel Naranjo, Guohui Liu, Shouryadeep Srivastava, Michael W.N. Deininger

ABSTRACT 7502

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.

SESSION

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

AUTHOR(S)

Jeff P. Shaman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D Lunin, Alexander Zweibach, Mikhail Shtivelband, Patrick M. Travis, Jason Claud Chandler, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Ian Flinn

ABSTRACT / POSTER 8022 • 355

Developmental Therapeutics - Immunotherapy

Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.

SESSION

Developmental Therapeutics—Immunotherapy

AUTHOR(S)

Landon Carter Brown, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew D Tucker, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Tian Zhang, Michael Roger Harrison, Daniel J. George, Ajjai Shivaram Alva, Emmanuel S. Antonarakis, Andrew J. Armstrong

ABSTRACT 3007

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

SESSION

Developmental Therapeutics—Immunotherapy

AUTHOR(S)

David E. Kozono, Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler J. Zemla, Yujia Wen, Mark Watson, Elie G. Dib, John M. Kirkwood, Gary H. Lyman, Jarushka Naidoo, Andrew B. Nixon, Elizabeth A. Mittendorf

ABSTRACT / POSTER TPS3154 • 218

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

SESSION

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

AUTHOR(S)

Martin Gutierrez, Vivek Subbiah, John J. Nemunaitis, Niharika B. Mettu, Kyriakos P. Papadopoulos, Minal A. Barve, Luis Féliz, Christine Francis Lihou, Chenwei Tian, Tao Ji, Ian M. Silverman, Rashmi Chugh, Mansoor N. Saleh

ABSTRACT / POSTER 3606 • 336

Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors.

SESSION

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

AUTHOR(S)

Daniel Adams, Steven H. Lin, Harvey I. Pass, Saranya Chumsri, Rena G. Lapidus, Martin Edelman, Raymond C. Bergan, Susan Tsai, Rebecca Aft, Sreeraj Pillai, Mark Watson, Amy K. Kim, Kazuaki Chikamatsu, Masanori Hayashi, David M Loeb, Navin R. Pinto, R. Katherine Alpaugh, Cha-Mei Tang, Thai Huu Ho, Jeffrey R Marks

ABSTRACT / POSTER 3535 • 265

Symptoms and Survivorship

Patient-reported distress and healthcare utilization in patients with advanced cancer.

SESSION

Symptoms and Survivorship

AUTHOR(S)

Jordan Danielle Hildenbrand, Heesu Park, David Casarett, Alicia Ellis, Kris Herring, Arif Kamal, Steve Power, Jesse D Troy, Steven Wolf, Yousuf Zafar, Thomas William LeBlanc

ABSTRACT / POSTER 12093 • 381

Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).

SESSION

Symptoms and Survivorship

AUTHOR(S)

Areej El-Jawahri, Thomas William LeBlanc, Alison Kavanaugh, Jason Webb, Vicki A. Jackson, Toby Christopher Campbell, Nina O'Connor, Selina M. Luger, Ellin Gafford, Jillian Gustin, Bhavana Bhatnagar, Amir Tahmasb Fathi, Gabriela Hobbs, Julia Foster, Showly Nicholson, Debra M. Davis, Hilena Addis, Dagny Vaughn, Nora K. Horick, Jennifer Temel

ABSTRACT 12000

Impact of palliative care on end-of-life outcomes in hematologic malignancies.

SESSION

Symptoms and Survivorship

AUTHOR(S)

Ari Pelcovits, Dominic Decker, Dana Guyer, Thomas William LeBlanc, Adam J. Olszewski, Pamela Egan

ABSTRACT / POSTER 12026 • 314

Cancer Prevention, Risk Reduction and Genetics

Genetic counseling referrals after next generation sequencing testing.

SESSION

Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)

Rafael Gonzalez, Emma Ryan, Catherine Watson, Gloria Broadwater, Noah D. Kauff, Laura J Havrilesky, Andrew Berchuck, John H. Strickler, Edgardo Castellar, Carolyn S. Menendez, Michelle Green, Kyle C Strickland, Rebecca A. Previs

ABSTRACT / POSTER 1515 • 7

The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.

SESSION

Cancer Prevention, Risk Reduction, and Genetics

AUTHOR(S)

Catherine Watson, Sarah Tait, Lindsay Soo, Jennifer Kay Plichta, Tian Zhang, Edgardo Castellar, Andrew J. Armstrong, Rebecca A. Previs, John H. Strickler, Michelle Green, Michael Datto, Paul Kelly Marcom, Carolyn S. Menendez

ABSTRACT / POSTER 1516 • 8

GYN Oncology

Ovarian cancer clinical trials: Study the studies to terminate the terminations.

SESSION

Gynecologic Cancer

AUTHOR(S)

Daniel Spinosa, Elizabeth Howell, D'Erryl Williams, Catherine Watson, Tomi F. Akinyemiju, Rebecca A. Previs

ABSTRACT / POSTER 6069 • 240

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

SESSION

Gynecologic Cancer

AUTHOR(S)

Rebecca Christian Arend, Bradley J. Monk, Robert Allen Burger, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Roni Shapira, Krishnansu Sujata Tewari, Marilyn Huang, Amnon Amit, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson

ABSTRACT / POSTER TPS6097 • 268

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

SESSION

Gynecologic Cancer

AUTHOR(S)

Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Gillette Cloven, Carolyn Muller, David Bender, Richard G. Moore, David Paul Michelin, Steven E. Waggoner, Melissa Ann Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman

ABSTRACT 6003

Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancer—A NRG/GOG ancillary analysis.

SESSION

Gynecologic Cancer

AUTHOR(S)

Kimberly Levinson, Anna Beavis, Christopher Purdy, Anne Rositch, Akila Viswanathan, Aaron Howard Wolfson, Michael Greg Kelly, Krishnansu Tewari, Leah McNally, Saketh R Guntupalli, Omar Ragab, Yi-Chun Lee, David S. Miller, Warner King Huh, Kelly Jeanes Wilkinson, Nicola M. Spirtos, Linda Van Le, Yovanni Casablanca, Laura L. Holman, Amanda Nickles Fader

ABSTRACT / POSTER 6019 • 190

Care Delivery and Regulatory Policy

Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA National Precision Oncology Program.

SESSION

Care Delivery and Regulatory Policy (Oral Abstract; 5/29/2020, 8-11 am)

AUTHOR(S)

Vishal Vashista, Jenna Armstrong, David Winski, Meghan Price, Bradley J. Hintze, Pradeep Poonnen, Jane Snowdon, Gretchen Purcell Jackson, Dilhan Weeraratne, David Brotman, Neil L. Spector, Michael J. Kelley

ABSTRACT 2005

ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).

SESSION

Care Delivery and Regulatory Policy

AUTHOR(S)

Matthew T Campbell, Tian Zhang, Lynda Chin, Allison Betof Warner, Matthen Mathew

ABSTRACT / POSTER TPS2089 • 81

Multi-institutional comparative effectiveness of advanced cancer longitudinal imaging response evaluation methods: Current practice versus artificial intelligence-assisted.

SESSION

Care Delivery and Regulatory Policy

AUTHOR(S)

Andrew Dennis Smith, Brian C. Allen, Asser Abou Elkasseem, Rafah Mresh, Seth T. Lirette, Yujan Shrestha, J. David Giese, Reece Stevens, Dillon Williams, Ahmed Farag, Ahmed Khalaf

ABSTRACT / POSTER 2010 • 2

Changes in cancer mortality rates after the adoption of the Affordable Care Act.

SESSION

Care Delivery and Regulatory Policy

AUTHOR(S)

Anna Lee, Kanan Shah, Junzo P. Chino, Fumiko Chino

ABSTRACT 2003

Out-of-pocket cost of screening with breast MRI for women at high risk for breast cancer.

SESSION

Care Delivery and Regulatory Policy

AUTHOR(S)

I-Wen Pan, Kevin C. Oeffinger, Ya-Chen T. Shih; University of Texas MD Anderson Cancer Center, Houston, TX; Duke University, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX

ABSTRACT / POSTER 2017 • 9

Health Services Research and Quality Improvement

Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.

SESSION

Health Services Research and Quality Improvement

AUTHOR(S)

Emma Ryan, Julia Salinaro, Laura J Havrilesky, Brittany Anne Davidson

ABSTRACT / POSTER 7074 • 346

A randomized controlled trial (RCT) testing a mobile application (app) to identify cancer treatment-related financial assistance.

SESSION

Health Services Research and Quality Improvement

AUTHOR(S)

Aaron Tarnasky, George Nhat Tran, Jonathan Nicolla, Fred Andrew Paul Friedman, Steven Wolf, Jesse D Troy, Anthony Derek Sung, Kanan Shah, Jakob Oury, Jillian C Thompson, Ben Gagosian, Kathryn I. Pollak, Ian Manners, Yousuf Zafar

ABSTRACT / POSTER 7073 • 345

Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.

SESSION

Health Services Research and Quality Improvement

AUTHOR(S)

Pradeep Poonnen, Olivia Dong, David Winski, Shelby D. Reed, Vishal Vashistha, Jill S. Bates, Michael J. Kelley, Deepak Voora

ABSTRACT / POSTER 7075 • 347

Composite grading algorithm for National Cancer Institute's PRO-CTCAE.

SESSION

Health Services Research and Quality Improvement

AUTHOR(S)

Amylou C. Dueck, Claus C. Becker, Lauren J. Rogak, Deborah Schrag, Bryce Reeve, Patricia Spears, Mary Lou Smith, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Antonia Vickery Bennett, Tito R. Mendoza, Charles S. Cleeland, Jeff A. Sloan, Deborah Bruner, Gisela Schwab, Thomas Michael Atkinson, Gita Thanarajasingam, Monica M. Bertagnolli, Ethan M. Basch

ABSTRACT / POSTER 7018 • 290

Pediatric Oncology

Assisted reproductive technology outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study.

SESSION

Pediatric Oncology

AUTHOR(S)

Kimberly W. Keefe, Andrea Lanes, Kayla Stratton, Daniel M. Green, Eric Jessen Chow, Kevin C. Oeffinger, Sara Barton, Lisa Diller, Yutaka Yasui, Wendy M. Leisenring, Gregory T. Armstrong, Elizabeth S. Ginsburg

ABSTRACT / POSTER 10528 • 415

Neuromuscular dysfunction and associated health/socioeconomic outcomes: A report from the Childhood Cancer Survivor Study (CCSS).

SESSION

Pediatric Oncology

AUTHOR(S)

Rozalyn L Rodwin, Yan Chen, Yutaka Yasui, Wendy M. Leisenring, Todd M. Gibson, Paul C. Nathan, Rebecca M. Howell, Kevin R. Krull, Caroline Mohrmann, Robert J. Hayashi, Eric Jessen Chow, Kevin C. Oeffinger, Gregory T. Armstrong, Kirsten K. Ness, Nina S. Kadan-Lottick

ABSTRACT / POSTER 10546 • 433

Underdiagnosis and undertreatment of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report.

SESSION

Pediatric Oncology II

AUTHOR(S)

Eric Jessen Chow, Yan Chen, Gregory T. Armstrong, Laura-Mae Baldwin, Todd M. Gibson, Melissa M. Hudson, Aaron McDonald, Paul C. Nathan, Karen L Syrjala, Emily S. Tonorezos, Kevin C. Oeffinger, Yutaka Yasui

ABSTRACT 10515

Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥ 18 months with unfavorable histology and without MYCN amplification: A Children's Oncology Group (COG) report.

SESSION

Pediatric Oncology I

AUTHOR(S)

Navin R. Pinto, Arlene Naranjo, Emily Hibbits, Xiangming Ding, Rachele Tibbetts, Rebekah Kennedy, Ruthann Pfau, Michael D. Hogarty, Susan G. Kreissman, Meredith Irwin, Julie R. Park, Shahab Asgharzadeh

ABSTRACT 10502

HAGHL genetic variants increase first fracture risk (FFR) in female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort Study (SJLIFE).

SESSION

Pediatric Oncology

AUTHOR(S)

Cindy Im, Nan Li, Wonjong Moon, Lindsay M. Morton, Wendy M. Leisenring, Rebecca M. Howell, Kevin C. Oeffinger, Charles A. Sklar, Carmen Louise Wilson, Yadav Sapkota, Kirsten K. Ness, Melissa M. Hudson, Leslie L. Robison, Smita Bhatia, Gregory T. Armstrong, Yutaka Yasui

ABSTRACT / POSTER 10554 • 441

Treatment intensity and risk of chronic health conditions and late mortality among long-term survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.

SESSION

Pediatric Oncology

AUTHOR(S)

Brent R Weil, Daniel M. Green, Andrew J Murphy, Qi Liu, Rebecca M. Howell, Christopher Bertero Weldon, Elizabeth Anne Mullen, Arin L Madenci, Wendy M. Leisenring, Joseph Philip Neglia, Kevin C. Oeffinger, Amanda M. Termuhlen, Sogol Mostoufi-Moab, Jennifer Levine, Kevin R. Krull, Yutaka Yasui, Leslie L. Robison, Gregory T. Armstrong, Eric Jessen Chow, Saro Armenian

ABSTRACT / POSTER 10553 • 440

Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the childhood cancer survivor study and the St. Jude Lifetime Cohort.

SESSION

Pediatric Oncology

AUTHOR(S)

Matthew R. Trendowski, Jessica Baedke, Yadav Sapkota, Omar El Charif, Heather E. Wheeler, Wendy M. Leisenring, Leslie L. Robison, Melissa M. Hudson, Lindsay M. Morton, Kevin C. Oeffinger, Lois B. Travis, Rebecca M. Howell, Yutaka Yasui, Gregory T. Armstrong, Smita Bhatia, M. Eileen Dolan

ABSTRACT / POSTER 10550 • 437

Professional Development and Education Advances

Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study.

SESSION

Professional Development and Education Advances

AUTHOR(S)

Neal E. Ready, Apama Raj Parikh, Patrice Lazure, Morgan Peniuta, Marianne Davies, Monica Augustyniak, Jeffrey Caterino, Robert Lewandowski, Alexander J. Lazar, Suzanne Murray

ABSTRACT / POSTER 11028 • 285